Breast cancer vaccine HER-2/neu - GlaxoSmithKline

Drug Profile

Breast cancer vaccine HER-2/neu - GlaxoSmithKline

Alternative Names: HER-2/neu peptide vaccine - GlaxoSmithKline

Latest Information Update: 27 Apr 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Breast cancer

Most Recent Events

  • 13 Sep 2004 Corixa and GlaxoSmithKline have initiated a phase I trial for Breast cancer in USA
  • 31 Dec 2003 Discontinued - Phase-I for Lung cancer in USA (unspecified route)
  • 31 Dec 2003 Discontinued - Phase-I for Ovarian cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top